Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four antimicrobial agents—amphotericin B, cefotaxime, polymyxin E (colistin), and tobramycin. Each component has a distinct mechanism of action: - **Amphotericin B** is a polyene antifungal that binds to ergosterol in fungal cell membranes, creating pores that lead to cell death. - **Cefotaxime** is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. - **Polymyxin E (colistin)** is a cationic polypeptide antibiotic targeting Gram-negative bacteria by disrupting the bacterial outer membrane through interaction with lipopolysaccharides and phospholipids. - **Tobramycin** is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis. This combination may be used for selective decontamination in critically ill patients or for managing severe infections involving multidrug-resistant organisms. The rationale behind such combinations includes broad-spectrum coverage against both fungal and resistant Gram-negative pathogens[1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amphotericin B + cefotaxime + polymyxin E + tobramycin.